JP5872041B2 - 幹細胞由来微小胞を含む神経生成促進用組成物 - Google Patents

幹細胞由来微小胞を含む神経生成促進用組成物 Download PDF

Info

Publication number
JP5872041B2
JP5872041B2 JP2014525931A JP2014525931A JP5872041B2 JP 5872041 B2 JP5872041 B2 JP 5872041B2 JP 2014525931 A JP2014525931 A JP 2014525931A JP 2014525931 A JP2014525931 A JP 2014525931A JP 5872041 B2 JP5872041 B2 JP 5872041B2
Authority
JP
Japan
Prior art keywords
stem cells
nerve
cells
stem cell
ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014525931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524437A5 (https=
JP2014524437A (ja
Inventor
バン，オーヤン
ジューン ムーン，ギィオン
ジューン ムーン，ギィオン
エオン ヒー チョ
エオン ヒー チョ
スク ジェー キム
スク ジェー キム
ドン ヒー キム
ドン ヒー キム
ジン ヒー スン
ジン ヒー スン
Original Assignee
サムスン ライフ パブリック ウェルフェア ファンデーション
サムスン ライフ パブリック ウェルフェア ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サムスン ライフ パブリック ウェルフェア ファンデーション, サムスン ライフ パブリック ウェルフェア ファンデーション filed Critical サムスン ライフ パブリック ウェルフェア ファンデーション
Publication of JP2014524437A publication Critical patent/JP2014524437A/ja
Publication of JP2014524437A5 publication Critical patent/JP2014524437A5/ja
Application granted granted Critical
Publication of JP5872041B2 publication Critical patent/JP5872041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
JP2014525931A 2011-08-16 2012-08-14 幹細胞由来微小胞を含む神経生成促進用組成物 Active JP5872041B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2011-0081147 2011-08-16
KR20110081147 2011-08-16
KR1020120088778A KR101405437B1 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물
KR10-2012-0088778 2012-08-14
PCT/KR2012/006478 WO2013025042A2 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물

Publications (3)

Publication Number Publication Date
JP2014524437A JP2014524437A (ja) 2014-09-22
JP2014524437A5 JP2014524437A5 (https=) 2015-07-16
JP5872041B2 true JP5872041B2 (ja) 2016-03-01

Family

ID=47897528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525931A Active JP5872041B2 (ja) 2011-08-16 2012-08-14 幹細胞由来微小胞を含む神経生成促進用組成物

Country Status (5)

Country Link
US (2) US20150045298A1 (https=)
EP (1) EP2745840B1 (https=)
JP (1) JP5872041B2 (https=)
KR (1) KR101405437B1 (https=)
WO (1) WO2013025042A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201302468D0 (en) * 2013-02-12 2013-03-27 Reneuron Ltd Stem cell product
AU2013249786A1 (en) * 2012-04-16 2014-11-06 The Regents Of The University Of California Ocular therapeutics using embryonic stem cell microvesicles
KR101540698B1 (ko) * 2012-10-05 2015-07-30 사회복지법인 삼성생명공익재단 허혈혈청을 포함하는 줄기세포 활성화 촉진용 조성물 및 줄기세포의 활성화 촉진 방법
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
KR101662405B1 (ko) * 2013-12-12 2016-10-05 사회복지법인 삼성생명공익재단 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물
CN105520911A (zh) * 2014-09-30 2016-04-27 重庆润泽医药有限公司 一种奥拉西坦脂质微泡及其制备方法
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP3423070B1 (en) * 2016-03-03 2022-05-04 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
EP3308795A1 (en) * 2016-10-12 2018-04-18 Unicyte EV AG A composition of extracellular vesicles (evs) and medical uses thereof
EP3568143B1 (en) * 2017-01-11 2023-12-13 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
KR102184722B1 (ko) * 2018-01-31 2020-12-01 서울대학교산학협력단 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
US20210228643A1 (en) 2018-07-26 2021-07-29 Uniwersytet Jagiellonski N vivo delivery system of the genome dna modifying enzymes and the use thereof
KR102320800B1 (ko) * 2018-10-25 2021-11-02 사회복지법인 삼성생명공익재단 효능이 증진된 줄기세포 유래 미세소포, 이의 용도 및 효능강화 방법
US11351119B2 (en) 2018-10-25 2022-06-07 Samsung Life Public Welfare Foundation Stem cell-derived microvesicles with enhanced efficacy, use thereof, and method for enhancing efficacy
CN114306238A (zh) * 2020-09-29 2022-04-12 中山大学 囊泡在制备治疗肺部疾病的药物中的应用
WO2023055222A1 (ko) * 2021-10-01 2023-04-06 주식회사 입셀 유도만능줄기세포 배양 배지 유래 성분을 포함하는 조성물 내지 이의 용도
WO2024090922A1 (ko) * 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물
WO2025182103A1 (ja) * 2024-02-28 2025-09-04 セルソース株式会社 脳梗塞の機能予後改善用組成物
KR20260010585A (ko) * 2024-07-12 2026-01-21 (주) 테라베스트 조혈모세포 또는 자연살해세포 유래의 세포외 소포체 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617428A1 (en) * 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
EP2209481B1 (en) 2007-10-15 2013-03-13 Fresenius Medical Care Deutschland GmbH Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method
ES2523098T3 (es) * 2007-10-29 2014-11-20 Fresenius Medical Care Deutschland Gmbh Microvesícula (MV) derivada de células madre para su uso en la inhibición de la apoptosis inducida por un agente citostático
CA2711218C (en) * 2008-01-04 2019-08-06 Lydac Neuroscience Limited A method of producing a population of differentiated cells
CN102014934B (zh) * 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
WO2010070141A2 (en) * 2008-12-19 2010-06-24 Cellerix, S.A. Compositions comprising adipose stem cells
JP5667180B2 (ja) * 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
SG2014010698A (en) * 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states

Also Published As

Publication number Publication date
WO2013025042A3 (ko) 2013-06-13
KR101405437B1 (ko) 2014-06-11
JP2014524437A (ja) 2014-09-22
US20170368103A1 (en) 2017-12-28
EP2745840A4 (en) 2015-04-22
EP2745840A2 (en) 2014-06-25
EP2745840B1 (en) 2017-07-12
US10406180B2 (en) 2019-09-10
US20150045298A1 (en) 2015-02-12
KR20130019356A (ko) 2013-02-26
WO2013025042A2 (ko) 2013-02-21

Similar Documents

Publication Publication Date Title
JP5872041B2 (ja) 幹細胞由来微小胞を含む神経生成促進用組成物
JP7514349B2 (ja) ラニフィブラノールを含む、幹細胞由来エクソソーム生成促進及び幹細胞能増強用組成物
US20210213068A1 (en) Pluripotent stem cell for treatment of cerebral infarction
JP7101367B2 (ja) シナプス形成剤
KR101489728B1 (ko) 남조류의 정제된 성분 및 이용 방법
JP2016540014A (ja) 幹細胞由来のエキソソームを有効成分に含む脳血管疾患治療用薬学的組成物
JP2012529487A (ja) 脳疾患及び状態の予防及び治療のための組成物及び方法
US10293003B2 (en) Multilineage-differentiating stress enduring (MUSE) cells for treatment of chronic kidney disease
JP6868307B2 (ja) 脂肪幹細胞由来のエキソソームを有効成分として含む肝線維症予防または治療用の組成物
Machalińska et al. Neuroprotective and antiapoptotic activity of lineage‐negative bone marrow cells after intravitreal injection in a mouse model of acute retinal injury
JP7076709B2 (ja) 間葉系幹細胞活性化剤
JP7618191B2 (ja) 臓器線維症の予防または治療剤
JP2018111722A (ja) 脳梗塞治療のための多能性幹細胞
KR20150059671A (ko) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 파킨슨 증후군의 예방 또는 치료용 약제학적 조성물
Kondziolka Stem cell treatment for ischemic stroke recovery
KR101914580B1 (ko) 줄기세포 컨디션드 배지 분말을 포함하는 뇌신경 또는 척수신경 관련 질환 예방, 개선 또는 치료용 의약 조성물
Irfan et al. Modern Stem Cell Therapy of Cardiac and Neurodegenerative Disorders: Pluses and Minuses: Pros and Cons of Stem cell therapy in cardio-neuro disorders
KR20240177146A (ko) 분리된 미토콘드리아를 포함하는 조직 섬유화 예방 또는 치료용 조성물 및 이의 용도
WO2025170054A1 (ja) 脊髄梗塞治療のための多能性幹細胞
JP2007514706A (ja) 生物学的活性血清、その製造方法および使用
CN101108180A (zh) 银杏内酯b在制备防治视网膜变性疾病的药物中的应用
Stepien et al. Research Article Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results
MX2007016597A (es) Componente purificado de algas azules-verdes y metodo de uso

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160112

R150 Certificate of patent or registration of utility model

Ref document number: 5872041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250